NCT00553852View on ClinicalTrials.gov

Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity

PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

March 31, 2008

Conditions
ObesityGHD
Interventions
DRUG

Recombinant GH Saizen (Merck-Serono)

Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.

Trial Locations (1)

80131

Department of Molecular and Clinical Endocrinology and Oncology Federico II University, Naples

All Listed Sponsors
lead

Federico II University

OTHER

NCT00553852 - Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity | Biotech Hunter | Biotech Hunter